ReviewThe Lancet. Respiratory medicine2014
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.
Review in The Lancet. Respiratory medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 1 synthesis or guideline pooled it, 305 citations in OpenAlex.
- Unveiling the underestimated prevalence of HIV, HBV and TB triple infection in Asia, South America, and Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- A Prospective Cohort Study on the Usage, Safety, and Efficacy of Delamanid in Patients With Pulmonary Multidrug-Resistant Tuberculosis in South Korea.Open forum infectious diseases · 2025Trial
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.The New England journal of medicine · 2022Trial
- Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-ResistantBioMed research international · 2017Trial
- Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana's Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality.BMC infectious diseases · 2016Trial
- High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial.The American journal of clinical nutrition · 2015Trial
- Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.Antimicrobial agents and chemotherapy · 2015Trial
- Design, Synthesis, and Antimicrobial Activity of Novel Cyt-ACS medicinal chemistry letters · 2026Article
- Epidemiological Characteristics and Spatiotemporal Cluster Analysis of Multidrug-Resistant and Rifampicin-Resistant Tuberculosis Among Older People - China, 2019-2025.China CDC weekly · 2026Article
- Article
- Distinct mechanisms drive post-antibiotic Tuberculosis relapse post-cure versus post-treatment-failure.bioRxiv : the preprint server for biology · 2026Article
- Epidemiological Analysis of Tuberculosis in Nakfa District, Eritrea: A 14 Year Spatiotemporal Study and Implications for TB Control.Infection and drug resistance · 2026Article
- Analysis of factors influencing plasma concentrations of anti-TB drugs in pediatric TB patients.BMC infectious diseases · 2025Article
- Stress-driven emergence of heritable non-genetic drug resistance.Research square · 2025Article
- Cryo-EM and cryo-ET reveal the molecular architecture and host interactions of mycobacteriophage Douge.Cell reports · 2025Article
- Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours.Nature communications · 2025Article
- Article
- Evaluating Tuberculosis and Drug Resistance in Serbia: A Ten-Year Experience from a Tertiary Center.Antibiotics (Basel, Switzerland) · 2025Article
- Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.Current microbiology · 2025Article
- Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 4 countries.
Funding
Abstract
Extensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting economically active young adults, and has high mortality irrespective of HIV status. In some countries such as South Africa, drug-resistant tuberculosis represents less than 3% of all cases but consumes more than a third of the total national budget for tuberculosis, which is unsustainable and threatens to destabilise national tuberculosis programmes. However, concern about drug-resistant tuberculosis has been eclipsed by that of totally and extremely drug-resistant tuberculosis--ie, resistance to all or nearly all conventional first-line and second-line antituberculosis drugs. In this Review, we discuss the epidemiology, pathogenesis, diagnosis, management, implications for health-care workers, and ethical and medicolegal aspects of extensively drug-resistant tuberculosis and other resistant strains. Finally, we discuss the emerging problem of functionally untreatable tuberculosis, and the issues and challenges that it poses to public health and clinical practice. The emergence and growth of highly resistant strains of tuberculosis make the development of new drugs and rapid diagnostics for tuberculosis--and increased funding to strengthen global control efforts, research, and advocacy--even more pressing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.